Understanding the Scope and Claims of United States Patent 7,169,791
Introduction
United States Patent 7,169,791, titled "Inhibitors of tyrosine kinases," is a significant patent in the pharmaceutical industry, particularly in the treatment of neoplastic diseases such as leukemia. Here, we will delve into the details of this patent, including its scope, claims, and the broader patent landscape it inhabits.
Patent Overview
US7169791B2 was issued to cover inhibitors of tyrosine kinases, which are crucial enzymes involved in the signaling pathways that regulate cell division and growth. The patent is assigned to various entities over its lifespan but is primarily associated with pharmaceutical companies involved in cancer treatment research.
Claims and Scope
Main Claims
The patent claims cover a range of compounds, methods of synthesis, and their compositions, specifically targeting tyrosine kinases. Here are some key aspects of the claims:
- Compounds: The patent describes a series of substituted pyrimidinyl aminobenzamides, which are inhibitors of tyrosine kinases. These compounds are designed to treat neoplastic diseases, particularly leukemia[4].
- Synthesis Methods: The patent includes detailed methods for synthesizing these compounds, ensuring that the process is reproducible and efficient[4].
- Compositions: The claims also cover various compositions that include these inhibitors, which can be formulated for different dosage forms such as tablets, capsules, or other oral formulations[4].
Specific Chemical Structures
The patent specifies the chemical structures of the compounds, including details on the radicals, isomers, and tautomers. For example:
- The compounds may include lower alkyl groups, which are defined as having up to 7 carbon atoms, preferably up to 4 carbon atoms, and can be linear or branched[4].
- Any asymmetric carbon atoms may be present in the (R)-, (S)-, or (R,S)-configuration, with a preference for the (R)- or (S)-configuration[4].
Patent Expiration
The patent US7169791B2 is set to expire on January 4, 2024. This expiration date is crucial as it will allow generic versions of the drug to enter the market, potentially reducing costs and increasing accessibility for patients[1].
Impact on the Pharmaceutical Industry
Generic Competition
The expiration of this patent will open the door for generic manufacturers to produce versions of the drug, which could significantly impact the market. Generic drugs are often cheaper and can increase patient access to essential medications.
Research and Development
The expiration of this patent may also spur further research and development in the field of tyrosine kinase inhibitors. With the basic compounds no longer under patent protection, researchers may explore new formulations, combinations, or uses for these inhibitors.
Broader Patent Landscape
Patent Trends
The landscape of pharmaceutical patents is complex and dynamic. Patents like US7169791B2 are part of a larger ecosystem where patent scope and claims are continually being evaluated and refined. Research indicates that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].
Litigation and Licensing
Patent litigation and licensing are significant factors in the pharmaceutical industry. The expiration of a patent like US7169791B2 can reduce litigation costs and licensing complexities, allowing more companies to enter the market and innovate around existing compounds[3].
Industry Expert Insights
Industry experts often highlight the importance of patent expiration in driving innovation and competition. For example:
"The expiration of patents is a critical event in the pharmaceutical industry. It allows for the entry of generic drugs, which can significantly reduce healthcare costs and improve patient access to essential medications."[blockquote cite="Industry Expert"]
Statistics and Examples
- Market Impact: The expiration of drug patents can lead to a significant reduction in drug prices. For instance, generic versions of drugs can be up to 80% cheaper than their branded counterparts.
- Research Impetus: The expiration of patents can also drive new research. For example, the expiration of the patent for imatinib mesylate (Gleevec) has led to the development of new tyrosine kinase inhibitors with improved efficacy and safety profiles[2].
Conclusion
United States Patent 7,169,791 is a pivotal patent in the treatment of neoplastic diseases, particularly leukemia. Its expiration in 2024 will have significant implications for the pharmaceutical industry, including the potential for generic competition, reduced costs, and increased innovation.
Key Takeaways
- Patent Expiration: The patent is set to expire on January 4, 2024.
- Generic Competition: The expiration will allow generic manufacturers to produce versions of the drug.
- Research and Development: The expiration may spur further research and development in tyrosine kinase inhibitors.
- Industry Impact: The expiration can reduce litigation costs and licensing complexities.
- Patient Access: Generic versions can improve patient access to essential medications.
FAQs
-
What is the main focus of United States Patent 7,169,791?
- The patent focuses on inhibitors of tyrosine kinases, specifically substituted pyrimidinyl aminobenzamides, for treating neoplastic diseases like leukemia.
-
When is the patent set to expire?
- The patent is set to expire on January 4, 2024.
-
What are the potential impacts of the patent expiration on the pharmaceutical industry?
- The expiration can lead to generic competition, reduced costs, increased patient access, and further research and development in the field.
-
How do narrower claims affect the patent examination process?
- Narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].
-
What are some examples of other significant patents expiring in 2024?
- Other notable patents expiring in 2024 include those for drugs like olaparib and imatinib mesylate, which are used to treat various cancers[1].
Sources
- GreyB, "List - 54 Drug Patents Expiring in 2024," GreyB Blog.
- MDPI, "Innovations and Patent Trends in the Development of USFDA-Approved Small Molecule Cancer Therapeutics," MDPI.
- Hoover Institution, "Patent Claims and Patent Scope," Hoover Institution.
- Google Patents, "US7169791B2 - Inhibitors of tyrosine kinases," Google Patents.
- Drugs.com, "Generic Tasigna Availability," Drugs.com.
